^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersBIOMARKER:
FOXP3 expression
i
Other names: FOXP3, Forkhead Box P3, Forkhead Box Protein P3, FOXP3delta7
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
5d
FOXP3 expression in duodenal mucosa: Unique role in pathogenesis and differential diagnosis of celiac disease. (PubMed, Ann Diagn Pathol)
It also correlates with IEL in CD patients and is unaffected by the increase in IEL and the presence of gastric Helicobacter Pylori in the non-CD group. FOXP3 is a sensitive and specific marker for diagnosing CD despite inflammatory conditions resulting from non-CD causes.
Journal
|
FOXP3 (Forkhead Box P3)
|
FOXP3 overexpression • FOXP3 expression
6d
Stearoyl-CoA desaturase in CD4+ T cells suppresses tumor growth through activation of the CXCR3/CXCL11 axis in CD8+ T cells. (PubMed, Cell Biosci)
These findings illustrate that SCD not only orchestrates the differentiation of T helper cells, but also promotes the antitumor activity of CD8+ T cells, suggesting its function in adverse tumor microenvironments.
Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • TBX21 (T-Box Transcription Factor 21) • FOXP3 (Forkhead Box P3) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • SCD (Stearoyl-CoA Desaturase)
|
FOXP3 expression
8d
EZH2 Activates HTLV-1 bZIP Factor-Mediated TGF-β Signaling in Adult T-Cell Leukemia. (PubMed, J Med Virol)
Treatment of 3-Deazaneplanocin A, a specific inhibitor of EZH2 significantly inhibited the Foxp3 expression. Taken together, our results suggest that EZH2 may be involved in the differentiation of regulatory T cells through activating the HBZ-Smad3-TGF-β signaling axis, which is considered to be a key strategy for viral persistence.
Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • SMAD4 (SMAD family member 4) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3) • SMAD3 (SMAD Family Member 3)
|
EZH2 overexpression • FOXP3 expression
16d
Immune checkpoints PD1/PDL1, TIM3/GAL9 and key immune mediators landscape reveal differential expression dynamics on imatinib response in chronic myeloid leukemia. (PubMed, Ann Hematol)
Univariate and multivariate analyses showed heightened ARG1 levels and a transition from PD1/PDL1 dominance at 3 months to TIM3/GAL9 at 12 months in non-optimal responders (BCR::ABL1 ≥ 0.1%). Our longitudinal design offers a deeper exploration of immune gene expression dynamics in CML patients on imatinib, highlighting its potential implications for therapy outcomes.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ABL1 (ABL proto-oncogene 1) • PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL2 (Interleukin 2) • FOXP3 (Forkhead Box P3) • GATA3 (GATA binding protein 3) • IL4 (Interleukin 4)
|
IL2 expression • FOXP3 expression
|
imatinib
19d
Mitochondrial mechanisms in Treg cell regulation: Implications for immunotherapy and disease treatment. (PubMed, Mitochondrion)
Mitophagy, as part of mitochondrial quality control, also plays an essential role in preserving Treg function. Understanding the intricate interplay between mitochondrial dynamics and Treg metabolism provides valuable insights for developing novel therapeutic strategies to treat autoimmune disorders and enhance immunotherapy in cancer.
Review • Journal • IO biomarker
|
FOXP3 (Forkhead Box P3)
|
FOXP3 expression
26d
Transcription Factor Forkhead Box Protein 3 (FOXP3) as a Prognostic Indicator for Postoperative Outcomes in Patients with Breast Cancer: Establishment of a Prognostic Nomogram. (PubMed, Breast Cancer (Dove Med Press))
The good predictive clinical utility of FOXP3-based nomograms within the threshold probability range for different survival rates was demonstrated by calibration curve and decision curve analyses. FOXP3 expression serves as a crucial prognostic indicator in breast cancer patients, and may aid preoperative evaluation in clinical practice.
Journal
|
FOXP3 (Forkhead Box P3)
|
FOXP3 overexpression • FOXP3 expression
27d
Amphiregulin promotes activated regulatory T cell-suppressive function via the AREG/EGFR pathway in laryngeal squamous cell carcinoma. (PubMed, Head Face Med)
Collectively, this study revealed the role and mechanism of AREG in negative immune regulation, and targeting AREG might be a novel immunotherapy for LSCC.
Journal • IO biomarker
|
AREG (Amphiregulin) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
|
AREG expression • FOXP3 expression
|
gefitinib
1m
FOXP3+/CD8+ ratio associated with aggressive behavior in RUNX3-methylated diffuse esophagogastric junction tumor. (PubMed, Cancer Sci)
Multiomics data from The Cancer Genome Atlas linked CCL28 with RUNX3-suppressed diffuse histological subtypes of non-EBV/non-MSI-high GEA. Our data suggest that a high FOXP3+/CD8+ ratio at the invasive margin might indicate tumor immune escape via CCL28, particularly in the RUNX3-methylated diffuse histological subtype.
Journal • MSi-H Biomarker
|
MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3) • RUNX3 (RUNX Family Transcription Factor 3)
|
CD8 expression • FOXP3 expression
1m
The prognostic and therapeutic value of the tumor microenvironment and immune checkpoints in pancreatic neuroendocrine neoplasms. (PubMed, Sci Rep)
The immunological landscape of Pan-NEN offers potential prognostic value and therapeutic targets. The findings suggest that immunotherapy, particularly targeting the PD-1/PD-L1 pathway, may serve as a promising strategy for the treatment of Pan-NEN, especially for Pan-NEC patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • PD-L1 underexpression • PD-1 expression • CD163 expression • FOXP3 expression
1m
The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer. (PubMed, Technol Cancer Res Treat)
At baseline, a low expression level of miR-200c was significantly associated with overexpression of FOXP3, poor prognosis, and shorter time to progression. The findings suggest that miR-200c-3p may be a promising biomarker for predicting the response to Trastuzumab in HER2-MBC patients.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • MIR200C (MicroRNA 200c) • FOXP3 (Forkhead Box P3) • MIR200A (MicroRNA 200a) • MIR200 (MicroRNA 200)
|
HER-2 positive • HER-2 expression • FOXP3 overexpression • miR-200-c expression • FOXP3 expression
|
Herceptin (trastuzumab)
1m
Exploration of efficacy of the first-line treatment for advanced non-small cell lung cancer with primary MET-amplification: Retrospective evaluation of 36 cases. (PubMed, Int Immunopharmacol)
Immuno-chemotherapy is a first-line optional treatment strategy in addition to targeted therapy for NSCLC patients with primary METamp. Foxp3-negative expression better predicts the near-term efficacy of immunotherapy.
Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase) • PD-1 (Programmed cell death 1) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • MET amplification • PD-L1 negative • FOXP3 expression
1m
Tregs ST2 deficiency enhances the abscopal anti-tumor response induced by microwave ablation. (PubMed, Int Immunopharmacol)
Blocking IL-33/ST2 pathway in Tregs offers a new strategy for MWA in clinical studies of metastatic cancer.
Journal
|
CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IL33 (Interleukin 33) • ST2 (Suppression Of Tumorigenicity)
|
FOXP3 expression
1m
FOXP3 inhibits proliferation and migration by competitively inhibiting YAP1 in nasopharyngeal carcinoma. (PubMed, Oral Oncol)
Previous studies have shown that chlorpromazine (CPZ) can inhibit YAP1 expression...Collectively, our findings indicate that FOXP3 competitively binds TEAD4 to regulate YAP1 localization in the nucleus and cytoplasm to suppress NPC progression. Consequently, FOXP3 may be a prognostic indicator for HNSCC.
Journal
|
YAP1 (Yes associated protein 1) • FOXP3 (Forkhead Box P3) • TEAD4 (TEA Domain Transcription Factor 4)
|
FOXP3 expression
|
chlorpromazine
1m
Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial. (PubMed, Gynecol Oncol)
IP chemotherapy enhances the survival rates of patients with EOC with an immune-Hot phenotype in the tumor microenvironment prior to treatment. (Japan Registry of Clinical Trials number, jRCTs031180141.).
P3 data • Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • FOXP3 (Forkhead Box P3)
|
FOXP3 expression
|
carboplatin • paclitaxel
1m
PD-L1+ Lymphocytes Are Associated with CD4+, Foxp3+CD4+, IL17+CD4+ T Cells and Subtypes of Macrophages in Resected Early-Stage Non-Small Cell Lung Cancer. (PubMed, Int J Mol Sci)
An analysis of the tumour-immune phenotype revealed a significant association between PD-L1 expression and IL17+CD4+ and Foxp3+CD4+ immune phenotypes. PD-L1+ lymphocytes are associated with the distribution of CD4+, Foxp3+CD4+, IL17A+CD4+ T cells, M1 and M2 macrophages in TME of resected NSCLC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • IL17A (Interleukin 17A)
|
PD-L1 expression • FOXP3 expression
1m
Effect modification between HLA-F and CD56 markers reveals differences in survival for triple-negative breast cancer patients. (PubMed, Hum Immunol)
The study highlights the complex immune regulation in TNBC stressing the importance of evaluating the immune landscape of individual tumours to identify patients that can benefit from immunotherapy. The finding of an effect modulation between HLA-F and CD56 is one aspect.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • HLA-E (Major Histocompatibility Complex, Class I, E) • FOXP3 (Forkhead Box P3) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
PD-L1 expression • CD8 expression • FOXP3 expression
1m
Arctigenin ameliorates high-fat diet-induced metabolic disorders by reshaping gut microbiota and modulating GPR/HDAC3 and TLR4/NF-κB pathways. (PubMed, Phytomedicine)
This study first demonstrated that AG could modulate the gut microbiota and derived metabolites to repair intestinal damage and regulate hepatic metabolic pathways, thereby ameliorating metabolic disorders induced by HFD. These findings support the great potential of AG as a novel prebiotic to fight obesity and chronic metabolic diseases by targeting the gut microbiota.
Journal
|
TLR4 (Toll Like Receptor 4) • FOXP3 (Forkhead Box P3) • HDAC3 (Histone Deacetylase 3)
|
FOXP3 expression
1m
Relationships between tumor CD147 expression, tumor-infiltrating lymphocytes, and oncostatin M in hepatocellular carcinoma. (PubMed, Virchows Arch)
In HCC, CD147 expression is associated with an immunosuppressive TIME, characterized by increased FOXP3+ regulatory T cells and a correlation with OSM-positive cells. These results elucidate the potential mechanisms through which CD147 facilitates tumor-immune evasion, suggesting the CD147 - OSM axis as a promising target for therapeutic intervention in HCC.
Journal • Tumor-infiltrating lymphocyte
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3) • BSG (Basigin (Ok Blood Group))
|
FOXP3 expression
2ms
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma. (PubMed, Oncoimmunology)
These results highlight the importance of CD4+ T cells in immune response against ICC. Secondly, a subset of tumors with "hot" TIME represents potential candidates for ICI, while stimulation of STAT1 pathway could be a potential target to turn "cold" into "hot" TIME in ICC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • CD4 expression • FOXP3 expression
2ms
Investigation of High Frequency Irreversible Electroporation for Canine Spontaneous Primary Lung Tumor Ablation. (PubMed, Biomedicines)
Additionally, we preliminarily evaluated the technical feasibility of delivering H-FIRE percutaneously under CT guidance to canine lung tumor patients (n = 2). Overall, H-FIRE treatment was well tolerated with no adverse clinical events, and our results suggest H-FIRE potentially altered the tumor immune microenvironment.
Journal • IO biomarker
|
IL6 (Interleukin 6) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CASP3 (Caspase 3) • FOXP3 (Forkhead Box P3) • MRC1 (Mannose Receptor C-Type 1)
|
Inflammatory gene signature • IL6 expression • FOXP3 expression
2ms
Increased Frequency of Circulating Activated FOXP3+ Regulatory T Cell Subset in Patients with Chronic Lymphocytic Leukemia Is Associated with the Estimate of the Size of the Tumor Mass, STAT5 Signaling and Disease Course during Follow-Up of Patients on Therapy. (PubMed, Cancers (Basel))
The results suggesting that an aTreg fraction could represent a possible marker of a severe disease course with infectious complications. Augmented homeostatic STAT5 signalling could support aTreg expansion, as higher pSTAT5 levels were significantly correlated with an increased aTreg frequency among CD4+FOXP3+ T cells during the follow-up of patients on therapy, as well as following SARS-CoV-2 antigen-specific stimulation in vitro.
Journal
|
FOXP3 (Forkhead Box P3) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
|
FOXP3 expression
2ms
Cancer-associated SF3B1-K700E mutation controls immune responses by regulating Treg function via aberrant Anapc13 splicing. (PubMed, Sci Adv)
In addition, acute myeloid leukemia grows faster in aged, but not young, Sf3b1K700Efl/+/Foxp3YFP-Cre mice compared to Foxp3YFP-Cre mice. Our results highlight the impact of cancer-associated SF3B1 mutation on immune responses, which affect cancer development.
Journal
|
SF3B1 (Splicing Factor 3b Subunit 1) • CD4 (CD4 Molecule)
|
SF3B1 mutation • SF3B1 K700E • FOXP3 expression
2ms
Low CD86 expression is a predictive biomarker for clinical response to the therapeutic HPV vaccine, IGMKK16E7: Results of a post-hoc analysis. (PubMed, JNCI Cancer Spectr)
Low expression of CD86 in exfoliated cervical cells can be used as a pre-treatment biomarker to predict histological CR after IGMKK16E7 use.
Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • ITGAE (Integrin Subunit Alpha E) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
|
CTLA4 expression • CD4 expression • FOXP3 expression
2ms
Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations. (PubMed, Front Immunol)
This study underscored the potential for targeted therapeutic strategies, such as enhancing Treg activity to restore balance in autoimmune diseases or depleting Foxp3+Tregs to augment anti-tumor immune responses in cancer. These insights laid the groundwork for future research and clinical applications, emphasizing the critical role of Foxp3+Tregs in immune regulation and the advancement of next-generation immunotherapies.
Review • Journal • IO biomarker
|
CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
|
FOXP3 expression
2ms
Osteopontin Regulates Treg Cell Stability and Function with Implications for Anti-Tumor Immunity and Autoimmunity. (PubMed, Cancers (Basel))
Finally, we observed reduced Foxp3 and Helios expression in Opn-deficient Tregs compared to wild-type controls after in vitro activation. Our findings indicate that targeting Opn in Tregs reveals vigorous and effective ways of promoting Treg instability and dysfunction in the TME, facilitating anti-tumor immunity.
Journal
|
SPP1 (Secreted Phosphoprotein 1) • FOXP3 (Forkhead Box P3)
|
IKZF2 expression • FOXP3 expression
2ms
Correlation of Th17/Treg associated transcription factors with clinicopathological features of colorectal cancer and their prognostic significance. (PubMed, Am J Transl Res)
Th17/Treg associated TFs are of great significance for the prognosis evaluation of CRC, the imbalance of which can cause aggravation of the inflammatory reaction and promote malignancy of CRC.
Journal
|
FOXP3 (Forkhead Box P3) • IL17A (Interleukin 17A) • IL22 (Interleukin 22)
|
FOXP3 expression
2ms
The relationship between the tertiary lymphoid structure and immune-infiltrating cells in gastrointestinal cancers: A systematic review and meta-analysis. (PubMed, Immun Inflamm Dis)
The presence of TLS is significantly correlated with the infiltration of various immune cells in gastrointestinal cancers. To determine the ideal balance between the presence of mature TLS and appropriate immune cell infiltration, further high-quality and multicenter clinical studies need to be conducted.
Clinical • Retrospective data • Review • Journal
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD68 (CD68 Molecule) • FOXP3 (Forkhead Box P3) • ITGAE (Integrin Subunit Alpha E) • ITGAX (Integrin Subunit Alpha X)
|
FOXP3 expression
3ms
Changes in the tumor immune microenvironment during disease progression in clear cell ovarian cancer. (PubMed, Int J Gynecol Cancer)
We characterized the tumor immune microenvironment in patients with advanced-stage ovarian clear cell carcinoma. PD-L1 and CD8+T cell expression significantly increased after recurrence. Whether this could be used to select patients for immunotherapy in the recurrence setting should be investigated.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ARID1A (AT-rich interaction domain 1A) • CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • PIK3CA mutation • ARID1A mutation • CD8 expression • FOXP3 expression
3ms
Focusing on tumor and it's microenvironmental immune members for head and neck cancer patients. (PubMed, Pathol Res Pract)
These preliminary results demonstrate the alterations in expression levels of immunologic markers are associated with the clinical presentations of HNSCC.
Journal
|
PD-L1 (Programmed death ligand 1) • CD163 (CD163 Molecule) • FOXP3 (Forkhead Box P3) • ITGAX (Integrin Subunit Alpha X) • CD86 (CD86 Molecule) • FUT4 (Fucosyltransferase 4)
|
FOXP3 expression
3ms
Distribution characteristics of immune infiltration and lymphovascular invasion in patients with breast cancer skin recurrence. (PubMed, Cancer Immunol Immunother)
The immune microenvironment of breast cancer skin recurrence may be in a state of suppression, and this suppression may intensify with disease progression. The pattern of skin recurrence may be more inclined toward lymphatic invasion. Our study provides new insights into the biological behaviors of this disease and its response to immunotherapy.
Retrospective data • Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • FOXP3 (Forkhead Box P3) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
|
CD31 expression • FOXP3 expression
3ms
Antisense targeting of FOXP3+ Tregs to boost anti-tumor immunity. (PubMed, Front Immunol)
ASO FOXP3 Treg targeting in vivo and in vitro was accompanied by significant downregulation of multiple exhaustion markers, and by increased expression of perforin and granzyme-B by intratumoral T cells. To conclude, we report that targeting the key Treg transcription factor FOXP3, with ASO FOXP3, has a powerful anti-tumoral effect and enhances T cell response in vitro and in vivo.
Journal • IO biomarker
|
GZMB (Granzyme B) • FOXP3 (Forkhead Box P3) • PRF1 (Perforin 1)
|
FOXP3 expression
3ms
Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer. (PubMed, Asia Pac J Clin Oncol)
The TIME of ACC was the so-called immune desert type, which may explain the mechanisms of the poor response to ICPi in previous clinical trials. On the other hand, MEChigh was the immune-inflamed type, and this may support the rationale of ICPi for this pathological subtype.
Journal • Tumor mutational burden • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • MSR1 (Macrophage Scavenger Receptor 1)
|
FOXP3 expression
3ms
Immunoliposome-based targeted delivery of the CRISPR/Cas9gRNA-IL30 complex inhibits prostate cancer and prolongs survival. (PubMed, Exp Mol Med)
In the syngeneic PC model, IL30-targeting immunoliposomes downregulated NFKB1 expression and prevented intratumoral influx of CD11b+Gr-1+MDCs, Foxp3+Tregs, and NKp46+RORγt+ILC3, and prolonged host survival by inhibiting tumor progression. This study serves as a proof of principle that immunoliposome-based targeted delivery of Cas9gRNA-IL30 represent a potentially safe and effective strategy for PC treatment.
Journal • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • HGF (Hepatocyte growth factor) • CDH1 (Cadherin 1) • EFNB2 (Ephrin B2) • VEGFD (Vascular Endothelial Growth Factor D) • CCL2 (Chemokine (C-C motif) ligand 2) • ITGAM (Integrin, alpha M) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3) • SERPINE1 (Serpin Family E Member 1) • DKK3 (Dickkopf WNT Signaling Pathway Inhibitor 3) • IL1B (Interleukin 1, beta) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • PSCA (Prostate Stem Cell Antigen 2)
|
PTEN expression • CDH1 expression • NFKB1 expression • HGF expression • FOXP3 expression
3ms
Discovery of a proteolysis targeting chimera (PROTAC) as a potent regulator of FOXP3. (PubMed, Bioorg Med Chem Lett)
We further substantiate that P60-L3-VHL reduces the differentiation and Foxp3 expression in the in-vitro activated Tregs. Overall, our findings suggest that P60-L3-VHL inhibits Tregs differentiation by degrading the Foxp3, and it may have potential implications in cancer immunotherapy.
Journal • IO biomarker
|
FOXP3 (Forkhead Box P3)
|
FOXP3 expression
3ms
FOXP3+ regulatory T cells, mismatch repair proteins and BRAF V600E status in young-onset colorectal cancer. (PubMed, Malays J Pathol)
While most of the YOCRC had pMMR, others exhibited dMMR with loss of one or more MMR proteins. The presence of BRAFV600E demonstrated the YOCRC's sporadic nature. A high FOXP3+Treg expression was significantly associated with MMR and BRAFV600E status. Future research must be expanded to cover other hospitals to increase the sample size and include MLH1 hypermethylation testing.
Retrospective data • Journal • Mismatch repair
|
BRAF (B-raf proto-oncogene) • MLH1 (MutL homolog 1) • FOXP3 (Forkhead Box P3)
|
BRAF V600E • MSI-H/dMMR • BRAF V600 • FOXP3 expression
7ms
The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab. (PubMed, ESMO Open)
The wide spectrum of clinical responses to ICB supports that TNBC is a heterogeneous disease. Tumors with high TMB respond better to ICB. However, the optimal cut-off of 10 mutations (mut)/megabase (Mb) may not reflect the complexity of all tumor subtypes, despite its approval as a tumor-agnostic biomarker. Further studies are required to better elucidate the relevance of the tumor microenvironment and its components as potential predictive biomarkers in the context of ICB.
Retrospective data • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CCR4 (C-C Motif Chemokine Receptor 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • FOXP3 (Forkhead Box P3) • CCR8 (C-C Motif Chemokine Receptor 8)
|
PD-L1 expression • TMB-H • PD-L1 overexpression • FOXP3 expression
|
Keytruda (pembrolizumab)
7ms
CD74 supports accumulation and function of regulatory T cells in tumors. (PubMed, Nat Commun)
These observations are unique to tumor conditions as, at steady state, CD74KO-Treg phenotype, survival, and suppressive capacity are unaffected in vitro and in vivo. CD74 therefore emerges as a specific regulator of tumor-infiltrating Tregs and as a target to interfere with Treg anti-tumor activity.
Journal
|
CD74 (CD74 Molecule) • FOXP3 (Forkhead Box P3)
|
CD74 expression • MHC-II expression • FOXP3 expression
7ms
FOXP3: A Player of Immunogenetic Architecture in Lung Cancer. (PubMed, Genes (Basel))
Here, we review recent progress in understanding the FOXP3 role in the immunogenetic architecture of lung cancer, which is the leading cause of cancer-related death. We discuss the prognostic significance of tumor FOXP3 expression, tumor-infiltrating FOXP3-lymphocytes, tumor FOXP3 in tumor microenvironments and the potential of FOXP3-targeted therapy.
Review • Journal
|
FOXP3 (Forkhead Box P3)
|
FOXP3 expression
7ms
Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy. (PubMed, Clin Cancer Res)
Several iTMEs exist during tumor evolution and NACT impact on iTME is heterogeneous. Clustering analysis of patients, unravels several IC subsets within OC and can guide future personalized approaches. Targeting different checkpoints such as TIM-3, LAG-3 and IDO-1, more prevalent than PD-L1, could more effectively harness anti-tumor immunity in this anti-PD-L1 resistant malignancy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IDO1 (Indoleamine 2,3-dioxygenase 1) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • CD8 expression • HAVCR2 expression • IDO1 expression • FOXP3 expression
7ms
Evaluation of Th1/Th2, regulatory cytokines and transcriptional factor FoxP3 in sheep immunized with a partially protective and non-protective vaccine and challenged with Fasciola hepatica. (PubMed, Vet Res)
The lower expansion of FoxP3 T cells and lower increase of IFN-ɣ and IL-10 in the partially protected vaccinated group may be related with lower hepatic lesions and fluke burdens recorded in this group as compared to the other two infected groups. The most relevant change in regulatory cytokine gene expression was the significant increase of TGF-β in the liver of IC, V1 and V2 groups as compared to the UC group, which could be related to hepatic lesions.
Journal
|
IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3) • IL4 (Interleukin 4)
|
FOXP3 expression
8ms
Inefficient recruitment of DDX39B impedes pre-spliceosome assembly on FOXP3 introns. (PubMed, RNA)
We propose that this is due to an altered conformation that U2AF2 adopts when it binds to C-rich/U-poor py tracts and that this conformation has a lower affinity for DDX39B. As a consequence, CCs assembled on FOXP3 introns are defective in recruiting DDX39B and this leads to inefficient assembly of pre-spliceosome complexes.
Journal
|
FOXP3 (Forkhead Box P3) • DDX39B (DExD-Box Helicase 39B)
|
FOXP3 expression
8ms
The Potential of FOXP3 in Predicting Survival and Treatment Response in Breast Cancer. (PubMed, Int J Gen Med)
FOXP3 stands out as an influential factor in BRCA, highlighting its diagnostic accuracy and prognostic value. Its association with immune responses and treatment efficacy opens new avenues for research and clinical applications, positioning FOXP3 as a vital target for further investigation in BRCA management.
Journal • Tumor mutational burden • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • BRCA (Breast cancer early onset) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • FOXP3 (Forkhead Box P3)
|
FOXP3 expression
Share via
